The trial involved delivery of a protein therapy directly into the brains of Parkinson’s patients.
LONDON - An experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients, scientists said on Wednesday, although they cautioned that a clinical trial was not able to prove the treatment slowed or halted the neurodegenerative disease. Scientists said some brain scans revealed “extremely promising” effects on damaged neurons of those who received the treatment.
results, learn more about the ground-breaking study, how the experimental treatment was delivered directly to the brain, and why the clinical trials were so pioneering pic.twitter.com/puViZdoFeK— Parkinson's UK February 27, 2019 Half of the patients were given monthly infusions for a further nine months.Results showed some signs of improvements, Whone said, but there was no significant difference between the treatment and placebo groups. He said this was in part due to the sizeable placebo effect in this trial.The placebo effect has been known to confound clinical trials of treatments for conditions involving the brain, boosted by patients’ expectations that a potential treatment will work.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Mike Mangena's drug trial postponedThe case against former Kaizer Chiefs striker Mike “Sporo” Mangena has been postponed to April.
Read more »
Cell C announces CEO Jose Dos Santos’s departure ahead of resultsJose Dos Santos will step down as CEO the day after parent company Blue Label Telecoms reports its interim results
Read more »
Cell C CEO makes the call to step downIt’s understood Jose dos Santos will take up a position as a consultant to the chairman of the Cell C board, in delivery of the company's strategic intent.
Read more »
Cell C courts new investors as CEO Jose dos Santos departsThe deal is aimed at reducing debt and boosting growth
Read more »
Markets LIVE: Cell C head Jose Dos Santos to step downThe mobile company announced on Friday afternoon that its CEO, Jose Dos Santos, would step down on March 1, 2019.
Read more »
Blue Label shakes up Cell C, pulls in new investorTwo years after buying a 45% stake in debt-laden Cell C, Blue Label Telecoms is shaking up management and pulling in a new investor to stem the losses.
Read more »
Dis-Chem is offering pap smears and prostate cancer screenings for R120 eachDis-Chem is offering pap smears and prostate cancer screenings for R120 each | BISouthAfrica
Read more »